SP1-induced PROX1-AS1 contributes to tumor progression by regulating miR-326/FBXL20 axis in colorectal cancer

Liu, Jing; Zhan, Wei; Chen, Gang; Yan, Shunkang; Chen, Wen; Li, Rui

doi:10.1016/j.cellsig.2022.110503

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…antisense RNA 1 (PROX1-AS1), which is involved in tumor growth and metastasis through proliferation, invasion and migration in some malignancies (79)(80)(81). Comprehensive studies on the methylation status of the PROX1-AS1 promoter region and expression in PDAC have not yet been performed.…”

Section: Discussionmentioning

confidence: 99%

DNA Methylation Biomarker Panels for the Differentiation of Hepatocellular Carcinoma and Cholangiocarcinoma from Liver Metastases from Colorectal Carcinoma and Pancreatic Adenocarcinoma

Draškovič,

Ranković,

Zidar

et al. 2024

Preprint

View full text Add to dashboard Cite

Background DNA methylation biomarkers are one of the most promising tools for the diagnosis and differentiation of adenocarcinomas of the liver, which are among the most common malignancies worldwide. Their differentiation is important because of the different prognosis and treatment options. This study validates novel diagnostic DNA methylation panels that focus on DNA hypermethylation in cancer and successfully differentiate between the two most common primary liver cancers (hepatocellular carcinoma and cholangiocarcinoma), two common metastatic liver cancers (from colorectal and pancreatic ductal adenocarcinomas) and healthy liver tissue. Moreover, this study investigates whether hypermethylation of selected DNA methylation biomarkers of primary colorectal carcinoma and pancreatic ductal adenocarcinoma are preserved in their liver metastases. Methods Our study included a cohort of 149 formalin-fixed, paraffin-embedded tissue samples. The methylation status of the samples was experimentally determined by methylation-sensitive high-resolution melting and methylation-specific digital PCR. The digital PCR results were additionally validated by bioinformatic analysis using an independent dataset of 487 samples from the TCGA and GEO databases. The sensitivities, specificities and diagnostic accuracies of the panels for individual cancer types were calculated. Results The methylation-sensitive high-resolution melting analysis led to the selection of the best biomarker candidates and enabled the development of panels that exhibit a sensitivity of 60–93% and a specificity of 85–98% for all included primary tumors and paired normal tissues. The panels tested with digital PCR show a sensitivity of 66.7–100%, a specificity of 94.9–100% and a diagnostic accuracy of 93–100% for hepatocellular carcinoma, cholangiocarcinoma, healthy liver tissue, colorectal liver metastases and liver metastases from pancreatic ductal adenocarcinoma. The bioinformatic analysis revealed similar sensitivities (64-97.4%), specificities (85–98%) and diagnostic accuracies (86–98%). Furthermore, the results show that DNA hypermethylation of the investigated promoter regions is preserved from primary colorectal carcinoma and pancreatic ductal adenocarcinoma to their liver metastases. Conclusions The new methylation biomarker panels exhibit high sensitivity, specificity and diagnostic accuracy and enable successful differentiation between primary and metastatic adenocarcinomas of the liver using methylation-specific digital PCR. A high concordance between methylation-sensitive high-resolution melting analysis, digital PCR and bioinformatic results from publicly available databases was achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

DNA Methylation Biomarker Panels for the Differentiation of Hepatocellular Carcinoma and Cholangiocarcinoma from Liver Metastases from Colorectal Carcinoma and Pancreatic Adenocarcinoma

Draškovič,

Ranković,

Zidar

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Li et al.’s research confirms that PROX1-AS1 can absorb miR-520d to upregulate PD-L1 in CRC ( 175 ), while Liu et al. discovered that the transcription factor SP1 activates the PROX1-AS1/miR-32/FBXL20 axis ( 176 ), both of which are involved in the regulation of CRC cell migration and invasion. Yu et al.’s results indicate that PVT1 can promote the metastasis of colon cancer by inhibiting the miR-30d-5p/RUNX2 axis ( 182 ).…”

Section: Lncrnas Regulate Invasion and Metastasismentioning

confidence: 96%

The functions and mechanisms of long non-coding RNA in colorectal cancer

Lin,

Zhao,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

CRC poses a significant challenge in the global health domain, with a high number of deaths attributed to this disease annually. If CRC is detected only in its advanced stages, the difficulty of treatment increases significantly. Therefore, biomarkers for the early detection of CRC play a crucial role in improving patient outcomes and increasing survival rates. The development of a reliable biomarker for early detection of CRC is particularly important for timely diagnosis and treatment. However, current methods for CRC detection, such as endoscopic examination, blood, and stool tests, have certain limitations and often only detect cases in the late stages. To overcome these constraints, researchers have turned their attention to molecular biomarkers, which are considered a promising approach to improving CRC detection. Non-invasive methods using biomarkers such as mRNA, circulating cell-free DNA, microRNA, LncRNA, and proteins can provide more reliable diagnostic information. These biomarkers can be found in blood, tissue, stool, and volatile organic compounds. Identifying molecular biomarkers with high sensitivity and specificity for the early and safe, economic, and easily measurable detection of CRC remains a significant challenge for researchers.

show abstract

SP1-induced PROX1-AS1 contributes to tumor progression by regulating miR-326/FBXL20 axis in colorectal cancer

Cited by 3 publications

References 22 publications

DNA Methylation Biomarker Panels for the Differentiation of Hepatocellular Carcinoma and Cholangiocarcinoma from Liver Metastases from Colorectal Carcinoma and Pancreatic Adenocarcinoma

DNA Methylation Biomarker Panels for the Differentiation of Hepatocellular Carcinoma and Cholangiocarcinoma from Liver Metastases from Colorectal Carcinoma and Pancreatic Adenocarcinoma

The functions and mechanisms of long non-coding RNA in colorectal cancer

Circ_0000518 regulates miR-326/EPHB3 axis to promote colorectal cancer progression

Contact Info

Product

Resources

About